Biotage AB launches share buy-back The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting's resolution to authorize the board to decide on the acquisition and sale of the company's own shares. At the Annual General Meeting held on 27 April 2009, the board was authorized to decide on the acquisition and sale of the company's own shares up and until the forthcoming Annual General Meeting. The shares acquired may not exceed 10 per cent of the total number of outstanding Biotage shares at any time. The purpose of the repurchase program is to give the board a wider freedom of action in the work with the company's capital structure and thereby improve shareholder value. Acquisition and sale of shares will take place on the NASDAQ OMX Stockholm at a price within the price interval at any time recorded. Biotage does not currently own any Biotage shares. Contact: Torben Jörgensen, President and CEO Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com This is information that Biotage AB (publ) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on June 22, 2009 at 11.00 CET About Biotage Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the area of medicinal chemistry. In 2005 business and products from the company Argonaut were acquired, further strengthening the product range in medicinal chemistry. The customers include the worlds top 30 pharma companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany and several other European countries. Biotage has 300 employees and had sales of SEK 385,3m in 2008. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: www.biotage.com
Biotage AB launches share buy-back
| Source: Biotage AB
Attachments
